Emerging nonsurgical methods for the treatment of vitreomacular adhesion: A review

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 1151-1165

  Schneider, Eric W ^a   Johnson, Mark W ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Macular edema; Macular hole; Microplasmin; Pharmacologic vitreolysis; Posterior vitreous detachment; Vitreomacular traction syndrome

Indexed keywords

ALPHA 2 ANTIPLASMIN; ARGINYLGLYCYLASPARTIC ACID; CHONDROITIN SULFATE; COLLAGEN FIBRIL; COLLAGEN TYPE 18; COLLAGENASE; DISPASE; FIBRONECTIN; HYALURONIDASE; LAMININ; N ACETYLGALACTOSAMINE 4 SULFATASE; NATTOKINASE; OCRIPLASMIN; PLACEBO; PLASMIN; PLASMINOGEN; SERINE PROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UREA DERIVATIVE; UROKINASE; VITREOSOLVE;

DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG BINDING SITE; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME INHIBITION; EYE TOXICITY; HUMAN; IRITIS; LOW DRUG DOSE; MOLECULAR BIOLOGY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA EDEMA; RETINA HEMORRHAGE; RETINA MACULA HOLE; RETINA MACULOPATHY; REVIEW; SINGLE DRUG DOSE; TREATMENT INDICATION; VITRECTOMY; VITREORETINOPATHY; VITREOUS BODY DETACHMENT; VITREOUS HEMORRHAGE;

EID: 80051736296     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s14840     Document Type: Review

References (162)

1. Akiba J, Quiroz MA, Trempe CL. Role of posterior vitreous detachment in idiopathic macular holes. Ophthalmology. 1990;97(12): 1610-1613.
2. Jaffe NS. Vitreous traction at the posterior pole of the fundus due to alterations in the vitreous posterior. Trans Am Acad Ophthalmol Otolaryngol. 1967;71(4):642-652.
3. Roldan M, Serrano JM. Macular edema and vitreous detachment. Ann Ophthalmol. 1989;21(4):141-148.
4. Nasrallah FP, Jalkh AE, Van Coppenolle F, et al. The role of the vitreous in diabetic macular edema. Ophthalmology. 1988;95(10): 1335-1339.
5. Akiba J, Arzabe CW, Trempe CL. Posterior vitreous detachment and neovascularization in diabetic retinopathy. Ophthalmology. 1990;97(7): 889-891.
6. Akiba J, Kado M, Kakehashi A, Trempe CL. Role of the vitreous in posterior segment neovascularization in central retinal vein occlusion. Ophthalmic Surg. 1991;22(9):498-502.
7. Robison CD, Krebs I, Binder S, et al. Vitreomacular adhesion in active and end-stage age-related macular degeneration. Am J Ophthalmol. 2009;148(1):79-82. e72.
8. Johnson MW. Perifoveal vitreous detachment and its macular complications. Trans Am Ophthalmol Soc. 2005;103:537-567.
9. Johnson MW. Posterior vitreous detachment: evolution and complications of its early stages. Am J Ophthalmol. 2010;149(3):371-382. e371.
10. Ranchod TM, Goldenberg DT, Trese MT. Pharmacologic vitreodynamics. Int Ophthalmol Clin. 2009;49(2):135-140.
11. Chu TG, Lopez PF, Cano MR, et al. Posterior vitreoschisis. An echographic finding in proliferative diabetic retinopathy. Ophthalmology. 1996;103(2):315-322.
12. Machemer R, Buettner H, Norton EW, Parel JM. Vitrectomy: a pars plana approach. Trans Am Acad Ophthalmol Otolaryngol. 1971; 75(4):813-820.
13. Sonoda KH, Sakamoto T, Enaida H, et al. Residual vitreous cortex after surgical posterior vitreous separation visualized by intravitreous triamcinolone acetonide. Ophthalmology. 2004;111(2): 226-230.
14. Russell SR, Hageman GS. Optic disc, foveal, and extrafoveal damage due to surgical separation of the vitreous. Arch Ophthalmol. 2001; 119(11):1653-1658.
15. Gandorfer A, Ulbig M, Kampik A. Plasmin-assisted vitrectomy eliminates cortical vitreous remnants. Eye (Lond). 2002;16(1):95-97.
16. Sebag J, Gupta P, Rosen RR, Garcia P, Sadun AA. Macular holes and macular pucker: the role of vitreoschisis as imaged by optical coherence tomography/scanning laser ophthalmoscopy. Trans Am Ophthalmol Soc. 2007;105:121-129; discussion 129-131.
17. Han DP, Abrams GW, Aaberg TM. Surgical excision of the attached posterior hyaloid. Arch Ophthalmol. 1988;106(7):998-1000.
18. Vander JF, Kleiner R. A method for induction of posterior vitreous detachment during vitrectomy. Retina. 1992;12(2):172-173.
19. Haritoglou C, Ehrt O, Gass CA, Kristin N, Kampik A. Paracentral scotomata: a new finding after vitrectomy for idiopathic macular hole. Br J Ophthalmol. 2001;85(2):231-233.
20. Thresher RJ, Ehrenberg M, Machemer R. Gas-mediated vitreous compression: an experimental alternative to mechanized vitrectomy. Graefes Arch Clin Exp Ophthalmol. 1984;221(5):192-198.
21. Miller B, Miller H, Ryan SJ. Experimental vitreous syneresis. Arch Ophthalmol. 1985;103(9):1385-1388.
22. Lincoff H, Kreissig I, Jakobiec F, Iwamoto T, Vitolo J, Shapiro R. Gas vitrectomy in a primate model. Graefes Arch Clin Exp Ophthalmol. 1986;224(3):215-217.
23. Luna JD, Artal MN, Reviglio VE, Pelizzari M, Diaz H, Juarez CP. Vitreoretinal alterations following laser in situ keratomileusis: clinical and experimental studies. Graefes Arch Clin Exp Ophthalmol. 2001;239(6): 416-423.
24. Venkatesh P, Vajpayee RB, Garg S. Induction of posterior vitreous separation using LASIK suction ring may have a potential role in the management of diabetic macular edema. Med Hypotheses. 2006; 66(6):1137-1139.
25. Sebag J. Pharmacologic vitreolysis. Retina. 1998;18(1):1-3.
26. Foulds WS. Is your vitreous really necessary? The role of the vitreous in the eye with particular reference to retinal attachment, detachment and the mode of action of vitreous substitutes. Eye (Lond). 1987; 1(Pt 6):641-664.
27. Bishop PN. Structural macromolecules and supramolecular organisation of the vitreous gel. Prog Retin Eye Res. 2000;19(3): 323-344.
28. Shui YB, Holekamp NM, Kramer BC, et al. The gel state of the vitreous and ascorbate-dependent oxygen consumption: relationship to the etiology of nuclear cataracts. Arch Ophthalmol. 2009;127(4): 475-482.
29. Holekamp NM. The vitreous gel: more than meets the eye. Am J Ophthalmol. 2010;149(1):32-36.
30. Bishop PN. Vitreous as a substrate for vitreolysis. Dev Ophthalmol. 2009;44:7-19.
31. Hindson VJ, Gallagher JT, Halfter W, Bishop PN. Opticin binds to heparan and chondroitin sulfate proteoglycans. Invest Ophthalmol Vis Sci. 2005;46(12):4417-4423.
32. Heegaard S, Jensen OA, Prause JU. Structure and composition of the inner limiting membrane of the retina. SEM on frozen resin-cracked and enzyme-digested retinas of Macaca mulatta. Graefes Arch Clin Exp Ophthalmol. 1986;224(4):355-360.
33. Kohno T, Sorgente N, Ishibashi T, Goodnight R, Ryan SJ. Immunofluorescent studies of fibronectin and laminin in the human eye. Invest Ophthalmol Vis Sci. 1987;28(3):506-514.
34. Ponsioen TL, van Luyn MJ, van der Worp RJ, van Meurs JC, Hooymans JM, Los LI. Collagen distribution in the human vitreoretinal interface. Invest Ophthalmol Vis Sci. 2008;49(9):4089-4095.
35. Sebag J, Balazs EA. Morphology and ultrastructure of human vitreous fibers. Invest Ophthalmol Vis Sci. 1989;30(8):1867-1871.
36. Foos RY. Vitreoretinal juncture; topographical variations. Invest Ophthalmol. 1972;11(10):801-808.
37. Wang J, McLeod D, Henson DB, Bishop PN. Age-dependent changes in the basal retinovitreous adhesion. Invest Ophthalmol Vis Sci. 2003;44(5):1793-1800.
38. Sebag J. Molecular biology of pharmacologic vitreolysis. Trans Am Ophthalmol Soc. 2005;103:473-494.
39. Terranova VP, Rohrbach DH, Martin GR. Role of laminin in the attachment of PAM 212 (epithelial) cells to basement membrane collagen. Cell. 1980;22(3):719-726.
40. Engvall E, Ruoslahti E, Miller EJ. Affinity of fibronectin to collagens of different genetic types and to fibrinogen. J Exp Med. 1978; 147(6):1584-1595.
41. Foos RY, Wheeler NC. Vitreoretinal juncture. Synchysis senilis and posterior vitreous detachment. Ophthalmology. 1982;89(12):1502-1512.
42. Sebag J. The vitreous: structure, function, and pathobiology. New York: Springer-Verlag; 1989.
43. Kishi S, Shimizu K. Posterior precortical vitreous pocket. Arch Ophthalmol. 1990;108(7):979-982.
44. Sebag J. Age-related changes in human vitreous structure. Graefes Arch Clin Exp Ophthalmol. 1987;225(2):89-93.
45. O'Malley P. The pattern of vitreous syneresis: a study of 800 autopsy eyes. In: Irvine AR, O'Malley C, editors. Advances in vitreous surgery. Springfield, IL: Thomas; 1976:17-33.
46. Larsson L, Osterlin S. Posterior vitreous detachment. A combined clinical and physiochemical study. Graefes Arch Clin Exp Ophthalmol. 1985;223(2):92-95.
47. Linder B. Acute posterior vitreous detachment and its retinal complications. Acta Ophthalmol. 1966;87(Suppl):1-108.
48. Sebag J. Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease. Graefes Arch Clin Exp Ophthalmol. 2004;242(8):690-698.
49. Kloti R. Experimental occlusion of retinal and ciliary vessels in owl monkeys. I. Technique and clinical observations of selective embolism of the central retinal artery system. Exp Eye Res. 1967;6(4): 393-399.
50. Sebag J. Age-related differences in the human vitreoretinal interface. Arch Ophthalmol. 1991;109(7):966-971.
51. Sebag J. Is pharmacologic vitreolysis brewing? Retina. 2002;22(1):1-3.
52. Ueno N, Sebag J, Hirokawa H, Chakrabarti B. Effects of visible-light irradiation on vitreous structure in the presence of a photosensitizer. Exp Eye Res. 1987;44(6):863-870.
53. Akiba J, Ueno N, Chakrabarti B. Mechanisms of photo-induced vitreous liquefaction. Curr Eye Res. 1994;13(7):505-512.
54. Kakehashi A, Ueno N, Chakrabarti B. Molecular mechanisms of photochemically induced posterior vitreous detachment. Ophthalmic Res. 1994;26(1):51-59.
55. Brown DJ, Bishop P, Hamdi H, Kenney MC. Cleavage of structural components of mammalian vitreous by endogenous matrix metalloproteinase-2. Curr Eye Res. 1996;15(4):439-445.
56. Vaughan-Thomas A, Gilbert SJ, Duance VC. Elevated levels of proteolytic enzymes in the aging human vitreous. Invest Ophthalmol Vis Sci. 2000;41(11):3299-3304.
57. Los LI, van der Worp RJ, van Luyn MJ, Hooymans JM. Age-related liquefaction of the human vitreous body: LM and TEM evaluation of the role of proteoglycans and collagen. Invest Ophthalmol Vis Sci. 2003; 44(7):2828-2833.
58. Moorhead LC, Chu HH, Garcia CA. Enzyme-assisted vitrectomy with bacterial collagenase. Time course and toxicity studies. Arch Ophthalmol. 1983;101(2):265-274.
59. Moorhead LC, Radtke N. Enzyme-assisted vitrectomy with bacterial collagenase. Pilot human studies. Retina. 1985;5(2):98-100.
60. Moorhead LC, Redburn DA, Kirkpatrick DS, Kretzer F. Bacterial collagenase. Proposed adjunct to vitrectomy with membranectomy. Arch Ophthalmol. 1980;98(10):1829-1839.
61. Verstraeten TC, Chapman C, Hartzer M, Winkler BS, Trese MT, Williams GA. Pharmacologic induction of posterior vitreous detachment in the rabbit. Arch Ophthalmol. 1993;111(6):849-854.
62. Harooni M, McMillan T, Refojo M. Efficacy and safety of enzymatic posterior vitreous detachment by intravitreal injection of hyaluronidase. Retina. 1998;18(1):16-22.
63. Tezel TH, Del Priore LV, Kaplan HJ. Posterior vitreous detachment with dispase. Retina. 1998;18(1):7-15.
64. Trese MT. Enzymatic-assisted vitrectomy. Eye (Lond). 2002;16(4): 365-368.
65. Trese MT. Enzymatic vitreous surgery. Semin Ophthalmol. 2000;15(2): 116-121.
66. Gandorfer A. Pharmacologic vitreolysis. Dev Ophthalmol. 2007;39: 149-156.
67. Gandorfer A. Enzymatic vitreous disruption. Eye (Lond). 2008;22(10): 1273-1277.
68. Bhisitkul RB. Anticipation for enzymatic vitreolysis. Br J Ophthalmol. 2001;85(1):1-2.
69. Benz MS, Packo KH, Gonzalez V, et al. A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy. Ophthalmology. 2010;117(4): 791-797.
70. Hermel M, Prenner J, Alabdulrazzak M, Dailey W, Hartzer M. Effect of intravitreal plasmin on vitreous removal through a 25-gauge cutting system in the rabbit in vivo. Graefes Arch Clin Exp Ophthalmol. 2009; 247(3):331-334.
71. Eckardt C. Transconjunctival sutureless 23-gauge vitrectomy. Retina. 2005;25(2):208-211.
72. Fujii GY, De Juan E Jr, Humayun MS, et al. A new 25-gauge instrument system for transconjunctival sutureless vitrectomy surgery. Ophthalmology. 2002;109(10):1807-1812; discussion 1813.
73. Ramkissoon YD, Aslam SA, Shah SP, Wong SC, Sullivan PM. Risk of iatrogenic peripheral retinal breaks in 20-G pars plana vitrectomy. Ophthalmology. 2010;117(9):1825-1830.
74. Tan HS, Mura M, de Smet MD. Iatrogenic retinal breaks in 25-gauge macular surgery. Am J Ophthalmol. 2009;148(3):427-430.
75. Hubschman JP, Gupta A, Bourla DH, Culjat M, Yu F, Schwartz SD. 20-, 23-, and 25-gauge vitreous cutters: performance and characteristics evaluation. Retina. 2008;28(2):249-257.
76. Teixeira A, Chong LP, Matsuoka N, et al. Vitreoretinal traction created by conventional cutters during vitrectomy. Ophthalmology. 2010; 117(7):1387-1392. e1382.
77. Asami T, Terasaki H, Kachi S, et al. Ultrastructure of internal limiting membrane removed during plasmin-assisted vitrectomy from eyes with diabetic macular edema. Ophthalmology. 2004;111(2):231-237.
78. Bonnet M. The development of severe proliferative vitreoretinopathy after retinal detachment surgery. Grade B: a determining risk factor. Graefes Arch Clin Exp Ophthalmol. 1988;226(3):201-205.
79. Capeans C, Lorenzo J, Santos L, et al. Comparative study of incomplete posterior vitreous detachment as a risk factor for proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1998;236(7):481-485.
80. Gandorfer A, Rohleder M, Grosselfinger S, Haritoglou C, Ulbig M, Kampik A. Epiretinal pathology of diffuse diabetic macular edema associated with vitreomacular traction. Am J Ophthalmol. 2005; 139(4):638-652.
81. Takahashi M, Trempe CL, Maguire K, McMeel JW. Vitreoretinal relationship in diabetic retinopathy. A biomicroscopic evaluation. Arch Ophthalmol. 1981;99(2):241-245.
82. Jalkh A, Takahashi M, Topilow HW, Trempe CL, McMeel JW. Prognostic value of vitreous findings in diabetic retinopathy. Arch Ophthalmol. 1982;100(3):432-434.
83. Kado M, Trempe CL. Role of the vitreous in branch retinal vein occlusion. Am J Ophthalmol. 1988;105(1):20-24.
84. Hikichi T, Konno S, Trempe CL. Role of the vitreous in central retinal vein occlusion. Retina. 1995;15(1):29-33.
85. Avunduk AM, Cetinkaya K, Kapicioglu Z, Kaya C. The effect of posterior vitreous detachment on the prognosis of branch retinal vein occlusion. Acta Ophthalmol Scand. 1997;75(4):441-442.
86. Krebs I, Brannath W, Glittenberg C, Zeiler F, Sebag J, Binder S. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol. 2007;144(5):741-746.
87. Lee SJ, Lee CS, Koh HJ. Posterior vitreomacular adhesion and risk of exudative age-related macular degeneration: paired eye study. Am J Ophthalmol. 2009;147(4):621-626. e621.
88. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol. 2005;140(4):573-584.
89. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol. 2005;140(4):585-597.
90. Sebag J. Pharmacologic vitreolysis-premise and promise of the first decade. Retina. 2009;29(7):871-874.
91. Mandl I. Collagenase. Science. 1970;169(951):1234-1238.
92. O'Neill R, Shea M. The effects of bacterial collagenase in rabbit vitreous. Can J Ophthalmol. 1973;8(2):366-370.
93. Quiroz H, Buzney SM, Furukawa H. Enzymatically induced posterior vitreous detachment [abstract]. Invest Ophthalmol Vis Sci (Suppl). 1984; 25:307.
94. Prabhakar V, Raman R, Capila I, Bosques CJ, Pojasek K, Sasisekharan R. Biochemical characterization of the chondroitinase ABC I active site. Biochem J. 2005;390(Pt 2):395-405.
95. Hageman GS, Russell SR. Chondroitinase-mediated disinsertion of the primate vitreous body [abstract]. Invest Ophthalmol Vis Sci (Suppl). 1994;35:1260.
96. Bishop PN, McLeod D, Reardon A. Effects of hyaluronan lyase, hyaluronidase, and chondroitin ABC lyase on mammalian vitreous gel. Invest Ophthalmol Vis Sci. 1999;40(10):2173-2178.
97. Staubach F, Nober V, Janknecht P. Enzyme-assisted vitrectomy in enucleated pig eyes: a comparison of hyaluronidase, chondroitinase, and plasmin. Curr Eye Res. 2004;29(4-5):261-268.
98. Hermel M, Schrage NF. Efficacy of plasmin enzymes and chondroitinase ABC in creating posterior vitreous separation in the pig: a masked, placebo-controlled in vivo study. Graefes Arch Clin Exp Ophthalmol. 2007;245(3):399-406.
99. Ludowieg J, Vennesland B, Dorfman A. The mechanism of action of hyaluronidase. J Biol Chem. 1961;236:333-339.
100. Menzel EJ, Farr C. Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses. Cancer Lett. 1998;131(1):3-11.
101. Foulds WS, Allan D, Moseley H, Kyle PM. Effect of intravitreal hyaluronidase on the clearance of tritiated water from the vitreous to the choroid. Br J Ophthalmol. 1985;69(7):529-532.
102. Gottlieb JL, Antoszyk AN, Hatchell DL, Saloupis P. The safety of intravitreal hyaluronidase. A clinical and histologic study. Invest Ophthalmol Vis Sci. 1990;31(11):2345-2352.
103. Kang SW, Hyung SM, Choi MY, Lee J. Induction of vitreolysis and vitreous detachment with hyaluronidase and perfluoropropane gas. Korean J Ophthalmol. 1995;9(2):69-78.
104. Hikichi T, Kado M, Yoshida A. Intravitreal injection of hyaluronidase cannot induce posterior vitreous detachment in the rabbit. Retina. 2000; 20(2):195-198.
105. Wang Z-L, Zhang X, Xu X, Sun X-D, Wang F. PVD following plasmin but not hyaluronidase: implications for combination pharmacologic vitreolysis therapy. Retina. 2005;25(1):38-43.
106. Stenn KS, Link R, Moellmann G, Madri J, Kuklinska E. Dispase, a neutral protease from Bacillus polymyxa, is a powerful fibronectinase and type IV collagenase. J Invest Dermatol. 1989;93(2):287-290.
107. Frenzel EM, Neely KA, Walsh AW, Cameron JD, Gregerson DS. A new model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1998;39(11):2157-2164.
108. Kralinger MT, Kieselbach GF, Voigt M, et al. Experimental model for proliferative vitreoretinopathy by intravitreal dispase: limited by zonulolysis and cataract. Ophthalmologica. 2006;220(4): 211-216.
109. Oliveira LB, Tatebayashi M, Mahmoud TH, Blackmon SM, Wong F, McCuen BW 2nd. Dispase facilitates posterior vitreous detachment during vitrectomy in young pigs. Retina. 2001;21(4):324-331.
110. Jorge R, Oyamaguchi EK, Cardillo JA, Gobbi A, Laicine EM, Haddad A. Intravitreal injection of dispase causes retinal hemorrhages in rabbit and human eyes. Curr Eye Res. 2003;26(2):107-112.
111. Zhu D, Chen H, Xu X. Effects of intravitreal dispase on vitreoretinal interface in rabbits. Curr Eye Res. 2006;31(11):935-946.
112. Wang F, Wang Z, Sun X, Xu X, Zhang X. Safety and efficacy of dispase and plasmin in pharmacologic vitreolysis. Invest Ophthalmol Vis Sci. 2004;45(9):3286-3290.
113. Sumi H, Hamada H, Tsushima H, Mihara H, Muraki H. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. Experientia. 1987;43(10):1110-1111.
114. Sumi H, Hamada H, Nakanishi K, Hiratani H. Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase. Acta Haematol. 1990;84(3):139-143.
115. Urano T, Ihara H, Umemura K, et al. The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis Cleaves and inactivates plasminogen activator inhibitor type 1. J Biol Chem. 2001;276(27): 24690-24696.
116. Takano A, Hirata A, Ogasawara K, et al. Posterior vitreous detachment induced by nattokinase (subtilisin NAT): a novel enzyme for pharmacologic vitreolysis. Invest Ophthalmol Vis Sci. 2006;47(5):2075-2079.
117. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 1981;41(11 Pt 1):4629-4636.
118. Uemura A, Nakamura M, Kachi S, et al. Effect of plasmin on laminin and fibronectin during plasmin-assisted vitrectomy. Arch Ophthalmol. 2005;123(2):209-213.
119. Li X, Shi X, Fan J. Posterior vitreous detachment with plasmin in the isolated human eye. Graefes Arch Clin Exp Ophthalmol. 2002;240(1): 56-62.
120. Takano A, Hirata A, Inomata Y, et al. Intravitreal plasmin injection activates endogenous matrix metalloproteinase-2 in rabbit and human vitreous. Am J Ophthalmol. 2005;140(4):654-660.
121. Baramova EN, Bajou K, Remacle A, et al. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett. 1997;405(2):157-162.
122. Wachtfogel YT, Abrams W, Kucich U, Weinbaum G, Schapira M, Colman RW. Fibronectin degradation products containing the cytoadhesive tetrapeptide stimulate human neutrophil degranulation. J Clin Invest. 1988;81(5):1310-1316.
123. Hikichi T, Yanagiya N, Kado M, Akiba J, Yoshida A. Posterior vitreous detachment induced by injection of plasmin and sulfur hexafluoride in the rabbit vitreous. Retina. 1999;19(1):55-58.
124. Gandorfer A, Putz E, Welge-Lussen U, Gruterich M, Ulbig M, Kampik A. Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy. Br J Ophthalmol. 2001;85(1):6-10.
125. Gandorfer A, Priglinger S, Schebitz K, et al. Vitreoretinal morphology of plasmin-treated human eyes. Am J Ophthalmol. 2002;133(1): 156-159.
126. Margherio AR, Margherio RR, Hartzer M, Trese MT, Williams GA, Ferrone PJ. Plasmin enzyme-assisted vitrectomy in traumatic pediatric macular holes. Ophthalmology. 1998;105(9):1617-1620.
127. Wu WC, Drenser KA, Trese MT, Williams GA, Capone A. Pediatric traumatic macular hole: results of autologous plasmin enzyme-assisted vitrectomy. Am J Ophthalmol. 2007;144(5):668-672.
128. Tsukahara Y, Honda S, Imai H, et al. Autologous plasmin-assisted vitrectomy for stage 5 retinopathy of prematurity: a preliminary trial. Am J Ophthalmol. 2007;144(1):139-141.
129. Wu W-C, Drenser KA, Lai M, Capone A, Trese MT. Plasmin enzymeassisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity. Retina. 2008;28(Suppl 3):S75-S80.
130. Wu W-C, Drenser KA, Capone A, Williams GA, Trese MT. Plasmin enzyme-assisted vitreoretinal surgery in congenital X-linked retinoschisis: surgical techniques based on a new classification system. Retina. 2007;27(8):1079-1085.
131. Trese MT, Williams GA, Hartzer MK. A new approach to stage 3 macular holes. Ophthalmology. 2000;107(8):1607-1611.
132. Rizzo S, Pellegrini G, Benocci F, Belting C, Baicchi U, Vispi M. Autologous plasmin for pharmacologic vitreolysis prepared 1 hour before surgery. Retina. 2006;26(7):792-796.
133. Sakuma T, Tanaka M, Inoue M, Mizota A, Souri M, Ichinose A. Efficacy of autologous plasmin for idiopathic macular hole surgery. Eur J Ophthalmol. 2005;15(6):787-794.
134. Azzolini C, D'Angelo A, Maestranzi G, et al. Intrasurgical plasmin enzyme in diabetic macular edema. Am J Ophthalmol. 2004;138(4):560-566.
135. Sakuma T, Tanaka M, Inoue J, Mizota A, Souri M, Ichinose A. Use of autologous plasmin during vitrectomy for diabetic maculopathy. Eur J Ophthalmol. 2006;16(1):138-140.
136. Hirata A, Takano A, Inomata Y, Yonemura N, Sagara N, Tanihara H. Plasmin-assisted vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: a pilot study. Retina. 2007;27(8):1074-1078.
137. Udaondo P, Diaz-Llopis M, Garcia-Delpech S, Salom D, Romero FJ. Intravitreal plasmin without vitrectomy for macular edema secondary to branch retinal vein occlusion. Arch Ophthalmol. 2011;129(3): 283-287.
138. Kamei M, Estafanous M, Lewis H. Tissue plasminogen activator in the treatment of vitreoretinal diseases. Semin Ophthalmol. 2000;15(1): 44-50.
139. Glacet-Bernard A, Kuhn D, Vine AK, Oubraham H, Coscas G, Soubrane G. Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. Br J Ophthalmol. 2000;84(6):609-613.
140. Le Mer Y, Korobelnik JF, Morel C, Ullern M, Berrod JP. TPA-assisted vitrectomy for proliferative diabetic retinopathy: results of a doublemasked, multicenter trial. Retina. 1999;19(5):378-382.
141. Esser P, Heimann K, Bartz-Schmidt KU, Walter P, Krott R, Weller M. Plasminogen in proliferative vitreoretinal disorders. Br J Ophthalmol. 1997;81(7):590-594.
142. Hesse L, Nebeling B, Schroeder B, Heller G, Kroll P. Induction of posterior vitreous detachment in rabbits by intravitreal injection of tissue plasminogen activator following cryopexy. Exp Eye Res. 2000;70(1):31-39.
143. Unal M, Peyman GA. The efficacy of plasminogen-urokinase combination in inducing posterior vitreous detachment. Retina. 2000;20(1): 69-75.
144. Men G, Peyman GA, Genaidy M, et al. The role of recombinant lysine-plasminogen and recombinant urokinase and sulfur hexafluoride combination in inducing posterior vitreous detachment. Retina. 2004; 24(2):199-209.
145. Hesse L, Kroll P. TPA-assisted vitrectomy for proliferative diabetic retinopathy. Retina. 2000;20(3):317-318.
146. Murakami T, Takagi H, Ohashi H, et al. Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion. Retina. 2007;27(8): 1031-1037.
147. Nagai N, Demarsin E, Van Hoef B, et al. Recombinant human microplasmin: production and potential therapeutic properties. J Thromb Haemost. 2003;1(2):307-313.
148. Gandorfer A, Rohleder M, Sethi C, et al. Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci. 2004;45(2): 641-647.
149. Sakuma T, Tanaka M, Mizota A, Inoue J, Pakola S. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes. Invest Ophthalmol Vis Sci. 2005;46(9):3295-3299.
150. Chen W, Huang X, Ma XW, Mo W, Wang WJ, Song HY. Enzymatic vitreolysis with recombinant microplasminogen and tissue plasminogen activator. Eye (Lond). 2008;22(2):300-307.
151. de Smet MD, Valmaggia C, Zarranz-Ventura J, Willekens B. Microplasmin: ex vivo characterization of its activity in porcine vitreous. Invest Ophthalmol Vis Sci. 2009;50(2):814-819.
152. de Smet MD, Gandorfer A, Stalmans P, et al. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. Ophthalmology. 2009;116(7):1349-1355, 1355. e1341-e1342.
153. Stalmans P, Delaey C, de Smet MD, van Dijkman E, Pakola S. Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial). Retina. 2010;30(7):1122-1127.
154. Dugel PU, Group M-TS. A single injection of ocriplasmin for the treatment of symptomatic vitreomacular adhesion (sVMA): results of the Phase III MIVI-TRUST Program [abstract]. Invest Ophthalmol Vis Sci (Suppl). 2011;52:6628.
155. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69(1):11-25.
156. Gehlsen KR, Argraves WS, Pierschbacher MD, Ruoslahti E. Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides. J Cell Biol. 1988;106(3):925-930.
157. Brem RB, Robbins SG, Wilson DJ, et al. Immunolocalization of integrins in the human retina. Invest Ophthalmol Vis Sci. 1994;35(9): 3466-3474.
158. Oliveira LB, Meyer CH, Kumar J, et al. RGD peptide-assisted vitrectomy to facilitate induction of a posterior vitreous detachment: a new principle in pharmacological vitreolysis. Curr Eye Res. 2002; 25(6):333-340.
159. Karageozian HL. Determine the safety and efficacy of Vitreosolve® administered intravitreally to induce a complete posterior vitreous detachment (PVD) in non proliferative diabetic retinopathy human subjects Invest Ophthalmol Vis Sci (Suppl). 2005;46:5453.
160. McLaughlin PS, McLaughlin BG. Chemical analysis of bovine and porcine vitreous humors: correlation of normal values with serum chemical values and changes with time and temperature. Am J Vet Res. 1987;48(3):467-473.
161. Gandorfer A, Kampik A. Pharmacologic vitreolysis combining the two enzymes plasmin and hyaluronidase. Retina. 2005;25(5):674; author reply 674-675.
162. Zhi-Liang W, Wo-Dong S, Min L, Xiao-Ping B, Jin J. Pharmacologic vitreolysis with plasmin and hyaluronidase in diabetic rats. Retina. 2009;29(2):269-274.